Inventor · disambiguated record
Ronnie Wei
Also filed as: WEI RONNIE · WEI RONNIE R · WEI RONNIE RONG
21 granted patents·24 pending applications·91 citations·filing 2012–2025
93Inventor score
Files withSANOFI SA16DRAGONFLY THERAPEUTICS INC11GENZYME CORP9MODEX THERAPEUTICS INC5MODEX THERAPEUTICS3
Top patents by PatentIndex Score
45 records- 0196US11192960B2Trispecific and/or trivalent binding proteinsSANOFI SA·Filed 2020·Granted Dec 7, 2021·6 cites·30 claims
- 0296US10882922B2Trispecific and/or trivalent binding proteinsSANOFI SA·Filed 2017·Granted Jan 5, 2021·20 cites·47 claims
- 0395US11530268B2Trispecific anti-CD38, anti-CD28, and anti-CD3 binding proteins and methods of use for treating viral infectionSANOFI SA·Filed 2019·Granted Dec 20, 2022·15 cites·34 claims
- 0494US11613576B2Trispecific binding proteins, methods, and uses thereofSANOFI SA·Filed 2020·Granted Mar 28, 2023·3 cites·29 claims
- 0594US11186649B2Anti-CD38 antibodies and methods of useSANOFI SA·Filed 2018·Granted Nov 30, 2021·10 cites·41 claims
- 0692US9834604B2Inhibitors of T-cell activationZHU YUNXIANG·Filed 2012·Granted Dec 5, 2017·22 cites·13 claims
- 0784US10626169B2Multispecific binding molecules having specificity to dystroglycan and laminin-2SANOFI SA·Filed 2018·Granted Apr 21, 2020·8 cites·17 claims
- 0884US2025002578A1Inhibitors of t-cell activationGENZYME CORP·Filed 2024·Application pending·0 cites
- 0982US12227573B2Trispecific binding proteins, methods, and uses thereofSANOFI SA·Filed 2023·Granted Feb 18, 2025·0 cites·45 claims
- 1080US2025154261A1Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1179US12275791B2Multi-specific binding proteins that bind HER2, NKG2D, and CD16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Apr 15, 2025·1 cites·6 claims
- 1279US12215157B2Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Feb 4, 2025·1 cites·40 claims
- 1376US12384851B2Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Aug 12, 2025·1 cites·30 claims
- 1475US12043665B2Inhibitors of T-cell activationGENZYME CORP·Filed 2021·Granted Jul 23, 2024·0 cites·12 claims
- 1574US12378318B2Proteins binding NKG2D, CD16 and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Aug 5, 2025·1 cites·11 claims
- 1674US2024417432A1Antigenic OspA PolypeptidesSANOFI SA·Filed 2024·Application pending·0 cites
- 1774US2024279362A1Trispecific and/or trivalent binding proteinsSANOFI SA·Filed 2024·Application pending·0 cites
- 1872US9708407B2Anti-CD52 antibodiesGENZYME CORP·Filed 2014·Granted Jul 18, 2017·2 cites·45 claims
- 1972US2023227553A1Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereofMODEX THERAPEUTICS·Filed 2022·Application pending·0 cites
- 2072US2023357401A1Trispecific anti-cd38, anti-cd28, and anti-cd3 binding proteins and methods of use for treating viral infectionSANOFI SA·Filed 2022·Application pending·0 cites
- 2171US2025250338A1Trispecific binding proteins, methods, and uses thereofSANOFI SA·Filed 2025·Application pending·0 cites
- 2271US2025250337A1Trispecific binding proteins, methods, and uses thereofSANOFI SA·Filed 2025·Application pending·0 cites
- 2371US2023203199A1Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereofMODEX THERAPEUTICS·Filed 2022·Application pending·0 cites
- 2471US2023235092A1Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereofMODEX THERAPEUTICS·Filed 2022·Application pending·0 cites
- 2571US2022380459A1Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2668US9783604B2Engineered anti-TGF-beta antibodies and antigen-binding fragmentsGENZYME CORP·Filed 2014·Granted Oct 10, 2017·1 cites·17 claims
- 2766US11932704B2Trispecific and/or trivalent binding proteinsSANOFI SA·Filed 2021·Granted Mar 19, 2024·0 cites·7 claims
- 2865US11505611B2FGFR3 antibodies and methods of useGENZYME CORP·Filed 2021·Granted Nov 22, 2022·0 cites·16 claims
- 2965US2023303704A1Fgfr3 antibodies and methods of useGENZYME CORP·Filed 2022·Application pending·0 cites
- 3065US2025161481A1Targeted lnp deliveryMODEX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3164US11028170B2Inhibitors of T-cell activationGENZYME CORP·Filed 2017·Granted Jun 8, 2021·0 cites·16 claims
- 3263US11993636B2Antigenic OspA polypeptidesSANOFI SA·Filed 2020·Granted May 28, 2024·0 cites·6 claims
- 3363US2025197481A1Antigen Binding Polypeptides, Antigen Binding Polypeptide Complexes and Methods of Use Thereof in HIVMODEX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3463US2022089760A1Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3563US2025206827A1Multi-specific binding proteins that bind her2, nkg2d, and cd16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3662US2024059798A1Conditionally activated antigen binding polypeptide complexes and methods of use thereofMODEX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3760US10730936B2Engineered anti-TGF-β antibodies and antigen-binding fragmentsGENZYME CORP·Filed 2017·Granted Aug 4, 2020·0 cites·20 claims
- 3860US2024109955A1Anti-sars-cov-2 antigen binding polypeptides, polypeptide complexes and methods of use thereofMODEX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3959US2024034808A1Antigen binding polypeptide complexes containing extracellular domains of tnfsf ligandsMODEX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4057US2019054182A1Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infectionSANOFI SA·Filed 2016·Application pending·0 cites
- 4156US2022195065A1Pharmaceutical formulations and dosage regimens for multi-specific binding proteins that bind her2, nkg2d, and cd16 for cancer treatmentDRAGONFLY THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4252US2024117054A1Proteins binding nkg2d, cd16 and flt3DRAGONFLY THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4346US2021214436A1Multi-specific binding proteins and improvements thereonDRAGONFLY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4445US11254737B2Multispecific binding molecules having specificity to dystroglycan and laminin-2SANOFI SA·Filed 2020·Granted Feb 22, 2022·0 cites·38 claims
- 4544US2017349665A1Anti-cd52 antibodiesGENZYME CORP·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Ronnie Wei files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →